



DEPARTMENT OF THE ARMY
HEADQUARTERS, US ARMY MEDICAL COMMAND
2050 WORTH ROAD
FORT SAM HOUSTON, TEXAS 78234-6000

REPLY TO
ATTENTION OF

MCHO-CL-Q

13 FEB 2009

MEMORANDUM FOR Commanders, MEDCOM Regional Medical Commands

SUBJECT: Policy and Procedures for Credentialing and Privileging Clinical Psychologists to Prescribe Medications

1. Reference: Army Regulation 40-68, Clinical Quality Management, 26 Feb 04.
2. Policy: Clinical Psychologists with appropriate training may be privileged to prescribe medications for filling at the medical treatment facility (MTF) pharmacy.
3. Credentials: Clinical Psychologists who hold clinical privileges at an Army MTF may request privileges for prescribing psychotropic medications if they are a graduate of the Department of Defense Psychopharmacology Demonstration Project or meet all the following credentials requirements:
 - a. A Masters Degree in psychopharmacology from a regionally accredited university.
 - b. One year of clinical supervision by a board certified Psychiatrist or Psychologist with prescribing privileges in a Department of Defense (DoD) MTF. The year of supervision must include a breadth and depth of experience with a diverse patient population. MTFs wishing to provide this supervision should contact the Clinical Psychology Consultant prior to initiating the program.
 - c. A passing score (70% correct) on the Psychopharmacology Examination for Psychologists administered by the American Psychological Association College of Professional Psychology. The examination must have been taken within 24 months of the time of initial application for prescribing privileges.
4. Formulary: The specific formulary for a prescribing Psychologist will be determined by the MTF granting these privileges.
 - a. Psychologists typically prescribe medications from within the following classes of drugs: antidepressants, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, and Attention Deficit Hyperactivity Disorder/narcolepsy agents. A list of medications by category is provided in the enclosure. These tables were developed by the DoD Pharmacoeconomic Center.

MCHO-CL-Q

SUBJECT: Policy and Procedures for Credentialing and Privileging Clinical Psychologists to Prescribe Medications

b. In accordance with (IAW) AR 40-68, Chapter 7-2c: "For providers other than physicians, and dentists, the drugs approved for prescription writing will be based on the provider's scope of practice, and the beneficiary group services." In the case of Clinical Psychologists, an open formulary is not appropriate. "Prescription writing authorization, as recommended by the P&T Committee, approved by the credentials committee, and approved by the MTF commander will be annotated in the PCF as an addendum to the provider's delineation of clinical privileges."

5. Delineation of Privileges: Prescription privileges will be annotated on DA Form 5440-11, Delineation of Clinical Privileges - Clinical Psychology. Prescribing authority will be based on appropriate training and demonstrated competencies reflected in the psychologist's standing clinical privileges.

6. Supervision and Peer Review:

a. IAW AR 40-68, paragraph 7-2b, a physician must be designated to be available for consultation and collaboration. This availability may be telephonic.

b. The initial period of prescription privileges will include six months of case reviews by a prescribing Psychologist, Psychiatrist, or other qualified physician designated by the MTF to confirm appropriate prescribing practice. After this period, prescribing psychologists will participate in routine peer review among prescribing providers with similar prescription privileges IAW AR 40-68.

7. Continuing Education: Clinical Psychologists who hold prescription privileges at an Army MTF will ensure a portion of their professional continuing education includes topics in psychopharmacology.

8. Prescriptive Authority: Prescriptions written by Clinical Psychologists must be filled at the MTF pharmacy. Clinical Psychologists are not eligible for fee-waived Drug Enforcement Administration registration numbers.

9. My points of contact on this policy are COL Doreen Lounsbery, Chief, Quality Management Division, doreen.lounsbery@amedd.army.mil, (210) 221-6195 and COL Bruce Crow, Clinical Psychology Consultant, bruce.crow@amedd.army.mil, (210) 916-4342.

Encl


ERIC B. SCHOOMAKER
Lieutenant General, MC
Commanding

Psychiatric Meds by Category

Table 1: Antidepressants (excluding MAOs and TCAs)

Generic	Brand (Manufacturer)	Initial FDA approval date	Patent Listings/Expiration	FDA-Approved Indications (as of July 2005)
Selective Serotonin Reuptake Inhibitors (SSRIs)				
Citalopram	Celexa, generics	17 July 98	-	MDD
Escitalopram	Lexapro (Forest)	14 Aug 02	Patent/exclusivity through 2009; however, some analysts	MDD, GAD
Fluoxetine	Prozac (Lilly), generics	29 Dec 87	-	MDD, OCD, PD, bulimia (pediatric labeling MDD, OCD)
Fluoxetine 90 mg caps (weekly regimen)	Prozac Weekly (Lilly)	26 Feb 01	Patents through 2017, no unexpired exclusivity	MDD (maintenance of response only)
Fluoxetine (special packaging)	Sarafem (Lilly)	6 Jul 00	Patents through 2008; exclusivity expired 12 Jun 2005	PMDD
Fluvoxamine	Generics	5 Dec 94	-	OCD (depression outside U.S.)
Paroxetine HCl	Paxil (GSK), generics	29 Dec 92	-	MDD, GAD, OCD, PD, PTSD, SAD
Paroxetine HCl controlled release	Paxil CR (GSK)	16 Feb 99 (02 launch)	Patents through 2017; exclusivity through Jan 2007	MDD, PD, PMDD, SAD
Paroxetine mesylate	Pexeva (Synthon)	11 Mar 02	Patents through 2017; no unexpired exclusivity	MDD, OCD, PD
Sertraline	Zoloft (Pfizer)	30 Dec 91	Patents through 2012, but generics expected June 2006	MDD, OCD, PD, PTSD, PMDD, SAD
Serotonin – Norepinephrine Reuptake Inhibitors (SNRIs)				
Duloxetine	Cymbalta (Lilly)	3 Aug 04	Patents through at least 2009	MDD, DPNP
Venlafaxine	Effexor (Wyeth), generics	28 Dec 93	At least one generic version likely in 2006	MDD
Venlafaxine extended release	Effexor XR (Wyeth)	20 Oct 97	Generic availability unclear, authorized generic likely 2010	MDD, GAD, SAD
Serotonin-2 Antagonist/Reuptake Inhibitors (SARIs)				
Nefazodone	Generics only*	22 Dec 94	-	MDD
Trazodone	Desyrel, generics	24 Dec 81	-	MDD
Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs)				
Bupropion	Wellbutrin, generics	30 Dec 85	-	MDD
Bupropion sustained release	Wellbutrin SR, generics	4 Oct 96		MDD
Bupropion extended release	Wellbutrin XL	28 Aug 03	Patents through 2018; no unexpired exclusivity. Generic availability unclear.	MDD
Alpha-2 Receptor Antagonists				
Mirtazapine tablets	Remeron, generics	14 Jun 96		MDD
Mirtazapine ODT	Remeron SolTab, generics	12 Jan 01		MDD

ODT = Orally disintegrating tablets; MDD = Major Depressive Disorder, GAD = Generalized Anxiety Disorder, OCD = Obsessive Compulsive Disorder, PD = Panic Disorder, PTSD = Posttraumatic Stress Disorder, PMDD = Premenstrual Dysphoric Disorder; SAD = Social Anxiety Disorder; DPNP = Diabetic Peripheral Neuropathic Pain

*Serzone was withdrawn from the U.S. market effective 14 Jun 2004. Generic versions remain available.

Table 2: Monoamine Oxidase Inhibitor (MAOI) Antidepressants

Generic name	Brand name (approval date)	Formulations	Manufacturer	Generic
Isocarboxazid	Marplan (07/1959)	10 mg tablet	Oxford	No
Phenelzine	Nardil (06/1961)	15 mg tablet	Pfizer	No
Tranylcypromine	Parnate (02/1961)	10 mg tablet	GSK,	Yes
Selegiline transdermal system	Emsam (02/2006)	6mg/24 hr patch 9mg/24 hr patch 12mg/24 hr patch	BMS, Somerset Pharmaceuticals	No

Table 3 Tricyclic Antidepressants (TCAs)

Generic name	Brand name	Formulations	Manufacturer	Generic
Desipramine	Norpramin	10, 25, 50, 75 100, 150 mg tabs	various	Yes
Nortriptyline	Pamelor	10, 25, 50, 75 mg caps 10 mg/5 mL solution	various	Yes
Amitriptyline	Elavil	10, 25, 50, 75, 100, 150 mg tabs	various	Yes
Imipramine	Tofranil	10, 25, 50 mg tabs	various	Yes
Doxepin	Sinequan	10, 25, 50, 75 100, 150 mg caps 10 mg/5 mL solution	various	Yes

Table 4: Atypical Antipsychotics

Generic	Brand (Manufacturer)	Strengths & formulations	FDA approval date
Aripiprazole	Abilify (Otzuka / Bristol-Myers Squibb)	10-, 15-, 20-, and 30-mg tablets (2- and 5-mg tablets approved but not currently marketed)	Nov 02
Clozapine	Clozaril (Novartis), multiple generics	25- and 100-mg tablets	Sept 89
Olanzapine	Zyprexa (Lilly)	2.5-, 5-, 7.5-, 10-, 15-, 20-mg tablets; 5-, 10-, 15-, 20-mg orally disintegrating tablets	Sep 96
Quetiapine	Seroquel (AstraZeneca)	25-, 100-, 200-, 300-mg tablets	Sep 97
Risperidone	Risperdal (Janssen) -summer 2008 became generically available	0.25-, 0.5-, 1-, 2-, 3-, 4-mg tablets; 1 mg/ml oral solution (30 mL bottle)	Dec 93
Ziprasidone	Geodon (Pfizer)	20-, 40-, 60-, 80-mg capsules; lyophilized injection for IM administration* (single use vial; 20 mg/ml when reconstituted)	Feb 01 (oral); June 02 (IM)
Olanzapine / fluoxetine	Symbyax (Eli Lilly)	3 mg/25 mg 6 mg/25 mg; 6 mg/50 mg 12 mg/25 mg/12 mg/50 mg	

Table 5: Older Antipsychotics (all are generic)

Generic	Brand (Manufacturer)
Chlorpromazine	Thorazine
Fluphenazine	Prolixin
Haloperidol	Haldol
Loxapine	Loxitane
Molindone	Moban
Mesoridazine	Serentil
Perphenazine	Trilafon
Thioridazine	Mellaril
Thiothixene	Navane
Trifluoperazine	Stelazine

Table 6: Anticonvulsants used for Psychiatric Conditions

Generic	Brand	Strengths & formulations
Lithium carbonate	Eskalith; Eskalith CR Lithobid generic	300 mg cap; 450 mg ER tab 300 mg ER tab 300 mg tab; 150, 300, 600 mg tabs
Lithium citrate	Cibalith-S	8 meq/5 mL solution
Divalproex sodium	Depakote (generic) Depakote ER	125, 250, 500 mg delayed release tab 250, 500 mg ER tab
Valproic acid	Depakene	250 mg cap 250 mg/5 mL syrup
Gabapentin	Neurontin (generic)	100, 300, 400 mg caps 600, 800 mg tabs 250 mg/5mL solution
Topiramate	Topamax	25, 100, 200 mg tabs 15, 25 mg sprinkle caps
Lamotrigine	Lamictal	25, 100, 150, 200 mg tabs 2, 5, 25 mg chew tabs
Carbamazepine	Tegretol (generic) Tegretol XR Carbatrol	200 mg tab; 100 mg chew tab; suspension 100 mg/5 mL 100, 200, 400 mg ER tab 200, 300 mg ER cap
Oxcarbazepine	Trileptal	150, 300, 600 mg tab 300 mg/5mL suspension
Clonazepam	Klonopin	0.5 mg, 1, 2 mg tabs
Lorazepam	Ativan	0.5, 1, 2 mg tabs 2 mg/mL solution

Table 7: Miscellaneous drugs

Generic name	Brand name	Formulations	Manufacturer	Generic
Pregabalin	Lyrica	25, 50, 75, 100, 150, 200, 225, 300 mg	Pfizer	No

Table 8: Benzodiazepines (all are generic)

Generic	Brand
Chlordiazepoxide	Librium, Limbitrol, Librax
Diazepam	Valium
Oxazepam	Serax
Clorazepate	Tranxene
Clonazepam	Klonopin
Lorazepam	Ativan
Alprazolam	Xanax
Temazepam	Restoril
Triazolam	Halcion
Quazepam	Doral
Estazolam	Prosom

Table 9: ADHD/Narcolepsy Drugs

Generic Name	Trade Name	Dosages	Generic
Methylphenidate HCL	Concerta (MPH OROS)	18mg, 27mg, 38mg, 64mg	N
	Metadate CD (MPH CD)	10mg, 20mg, 30mg	Equiv to Ritalin SR
	Metadate ER (MPH ER)	10mg, 20mg	Equiv to Metylin ER
	Metylin	Chew 2.5mg, 5mg, 10mg IR: 5mg, 10mg, 20mg Oral Soln 5mg/5ml, 10mg/5ml ER 10mg, 20mg	IR Only
	Ritalin*	IR: 5mg, 10mg, 20mg	Y
	Ritalin SR (MPH SR)	20mg	Equiv to Metadate ER
	Ritalin LA (MPH SODAS)	10mg, 20mg, 30mg, 40mg	N
	Daytrana Patch	15mg, 20mg, 30mg	N
Amphetamine Mixture	Adderall	5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg	Y
	Adderall XR	5mg, 10mg, 15mg, 20mg, 30mg	N
Atomoxetine HCL	Strattera	18mg, 25mg, 40mg, 60mg, 80mg, 100mg	N
Dextroamphetamine	Dexedrine	5mg	Y
	Dextrostat	5mg, 10mg	Y
	Dexedrine Spansule	5mg, 10mg, 15mg	Y
Dexmethylphenidate	Focalin	IR: 2.5mg, 5mg, 10mg XR: 5mg, 10mg, 20mg	N
Methamphetamine	Desoxyn	5mg	Y
Modafinil	Provigil	100mg, 200mg	N
Na Oxybate	Xyrem	500mg/ml	N